An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS

AIDS Research and Human Retroviruses

Volumn 20, Issue 8, 2004, Pages 846-859

  Wang, Shainn Wei ^a,b   Bertley, Frederic M N ^a,b   Kozlowski, Pamela A ^a,b   Herrmann, Lara ^a,b   Manson, Kelledy ^c   Mazzara, Gail ^c   Piatak, Mike ^d   Johnson, R Paul ^b,e   Carville, Angela ^b   Mansfield, Keith ^b   Aldovini, Anna ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Therion Biologics Corporation   (United States)

^d SAIC FREDERICK INC   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DNA VACCINE; GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; POL PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VACCINIA VACCINE; VIRUS ANTIBODY; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SPECIFICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPROPHYLAXIS; LYMPHOCYTE COUNT; MACACA; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINIA VIRUS; VACCINIA VIRUS ANKARA;

ADMINISTRATION, RECTAL; AIDS VACCINES; ANIMALS; FUSION PROTEINS, GAG-POL; IMMUNITY, MUCOSAL; MACACA MULATTA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, SYNTHETIC; VACCINIA VIRUS; VESICULAR STOMATITIS-INDIANA VIRUS;

EID: 4344652157     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/0889222041725253     Document Type: Article

References (82)

1. UNAIDS/WHO: AIDS epidemic update: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO), 2002.
2. Robinson HL: New hope for an AIDS vaccine. Nat Rev Immunol 2002;2:239-250.
3. Walker CM, Moody DJ, Stites DP, and Levy JA: CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;234:1563-1566.
4. Borrow P, Lewicki H, Hahn BH, Shaw GM, and Oldstone MB: Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
5. Musey L, Hughes J, Schacker T, Shea T, Corey L, and McElrath MJ: Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997;337:1267-1274.
6. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo V, Hurley A, Markowitz M, Ho DD, Nixon DF, and McMichael AJ: Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-2106.
7. Ogg GS, Jin X, Bonhoeffer S, Moss P, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Hurley A, Markowitz M, Ho DD, McMichael AJ, and Nixon DF: Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999;73:797-800.
8. Kalams SA, Goulder PJ, Shea AK, Jones NG, Trocha AK, Ogg GS, and Walker BD: Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol 1999;73:6721-6728.
9. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma HL, Grimm BD, Hulsey ML, Miller J, McClure HM, McNicholl JM, Moss B, and Robinson HL: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74.
10. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Dresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, and Emini EA: Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-335.
11. Cao Y, Qin L, Zhang L, Safrit J, and Ho DD: Virologie and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332:201-208.
12. Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, Krivulka GR, Beaudry K, Lifton MA, Gorgone DA, Montefiori DC, Lewis MG, Wolinsky SM, and Letvin NL: Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002;415:335-359.
13. Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, Montefiori DC, O'Connor DH, Davis BT, Lee PK, Maier EL, Harlow J, Goulder PJ, Brander C, Rosenberg ES, and Walker BD: HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 2002;420:434-439.
14. Walker BD and Goulder PJ: AIDS. Escape from the immune system. Nature 2000;407:313-314.
15. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, Robbins GK, D'Aquila RT, Goulder PJ, and Walker BD: Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-526.
16. Hel Z, Nacsa J, Tryniszewska E, Tsai WP, Parks RW, Montefiori DC, Felber BK, Tartaglia J, Pavlakis GN, and Franchini G: Containment of simian immunodeficiency virus infection in vaccinated macaques: Correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J Immunol 2002;169:4778-4787.
17. Sarkar S, Kalia V, Murphey-Corb M, and Montelaro RC: Detailed analysis of CD4+ Th responses to envelope and Gag proteins of simian immunodeficiency virus reveals an exclusion of broadly reactive Th epitopes from the glycosylated regions of envelope. J Immunol 2002;168:4001-4011.
18. Wagner GS, Miller CJ, and McChesney MB: CD4+ T cells and monocytes elicited by immunization of rhesus monkeys with antigen-pulsed dendritic cells control SIV replication. AIDS Res Hum Retroviruses 2002;18:143-148.
19. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Lu Y, Wright JE, Chou TC, and Ruprecht RM: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000;6:200-206.
20. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, Ketas T, Marx PA, Klasse PJ, Burton DR, and Moore JP: Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003;9:343-346.
21. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, and Letvin NL: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000;290:486-492.
22. Egan MA, Charini WA, Kuroda MJ, Schmitz JE, Racz P, Tenner-Racz K, Manson K, Wyand M, Lifton MA, Nickerson CE, Fu T, Shiver JW, and Letvin NL: Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection. J Virol 2000;74:7485-7495.
23. Muthumani K, Kudchodkar S, Zhang D, Bagarazzi ML, Kim JJ, Boyer JD, Ayyavoo V, Pavlakis GN, and Weiner DB: Issues for improving multiplasmid DNA vaccines for HIV-1. Vaccine 2002;20:1999-2003.
24. Kim JJ, Yang JS, Dang K, Manson KH, and Weiner DB: Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Clin Cancer Res 2001;7:882s-889s.
25. Donnelly JJ, Ulmer JB, Shiver JW, and Liu MA: DNA vaccines. Annu Rev Immunol 1997;15:617-648.
26. Blanchard TJ, Alcami A, Andrea P, and Smith GL: Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine. J Gen Virol 1998;79(Pt. 5):1159-1167.
27. Sutter G and Moss B: Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992;89:10847-10851.
28. Cohen O, Weissman D, Fauci AS: The immunopathogenesis of HIV infection. In: Fundamental Immunology. Paul WE. (ed.). Lippincott-Raven, Philadelphia, 1998, pp. 1455-1509.
29. Belyakov IM, Berzofsky JA: Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 2004;20:247-253.
30. Kozlowski PA and Neutra MR: The role of mucosal immunity in prevention of HIV transmission. Curr Mol Med 2003;3:217-228.
31. Wang SW, Kozlowski PA, Schmelz G, Manson K, Wyand MS, Glickman R, Montefiori D, Lifson JD, Johnson RP, Neutra MR, and Aldovini A: Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions. J Virol 2000;74:10514-10522.
32. Kato H, Bukawa H, Hagiwara E, Xin KQ, Hamajima K, Kawamoto S, Sugiyama M, Noda E, Nishizaki M, and Okuda K: Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses. Vaccine 2000;18:1151-1160.
33. Belyakov IM, Hel Z, Kelsall B, Kuznetsov VA, Ahlers JD, Nacsa J, Watkins DI, Allen TM, Sette A, Altman J, Woodward R, Markham PD, Clements JD, Franchini G, Strober W, and Berzofsky JA: Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med 2001;7:1320-1326.
34. Stevceva L, Alvarez X, Lackner AA, Tryniszewska E, Kelsall B, Nacsa J, Tartaglia J, Strober W, and Franchini G: Both mucosal and systemic routes of immunization with the live, attenuated NY-VAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques. J Virol 2002;76:11659-11676.
35. Bertley F, Wang SW, Kozlowski, et al: . Control of SHIV viremia and disease progression after nasal mucosa vaccination with a DNA-MVA Prime-Boost Vaccination Regimen. J Immunology 2004;172:3745-3757.
36. Sakaue G, Hiroi T, Nakagawa Y, Someya K, Iwatani K, Sawa Y, Takahashi H, Honda M, Kunisawa J, and Kiyono H: HIV mucosal vaccine: Nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J Immunol 2003;170:495-502.
37. Hamajima K, Hoshino Y, Xin KQ, Hayashi F, Tadokoro K, and Okuda K: Systemic and mucosal immune responses in mice after rectal and vaginal immunization with HIV-DNA vaccine. Clin Immunol 2002;102:12-18.
38. Walther-Jallow L, Nilsson C, Soderlund J, ten Haaft P, Makitalo B, Biberfeld P, Bottiger P, Heeney J, Biberfeld G, and Thorstensson R: Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys. J Gen Virol 2001;82:1601-1612.
39. Earl PL, Wyatt LS, Montefiori DC, Bilska M, Woodward R, Markham PD, Malley JD, Vogel TU, Allen TM, Watkins DI, Miller N, and Moss B: Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology 2002;294:270-281.
40. Moss B, Carroll MW, Wyatt LS, Bennink JR, Hirsch VM, Goldstein S, Elkins WR, Fuerst TR, Lifson JD, Piatak M, Restifo NP, Overwijk W, Chamberlain R, Rosenberg SA, and Sutter G: Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 1996;397:7-13.
41. Kozlowski PA, Lynch RM, Patterson RR, Cu-Uvin S, Flanigan TP, and Neutra MR: Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. J Acquir Immune Defic Syndr 2000;24:297-309.
42. van der Meide PH, Groenestein RJ, de Labie MC, Heeney J, Pala P, and Slaoui M: Enumeration of lymphokine-secreting cells as a quantitative measure for cellular immune responses in rhesus macaques. J Med Primatol 1995;24:271-281.
43. Weynants V, Walravens K, Didembourg C, Flanagan P, Godfroid J, and Letesson JJ: Quantitative assessment by flow cytometry of T-lymphocytes producing antigen-specific gamma-interferon in Brucella immune cattle. Vet Immunol Immunopathol 1998;66:309-320.
44. Knapp LA, Lehmann E, Piekarczyk MS, Urvater JA, and Watkins DI: A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing. Tissue Antigens 1997;50:657-661.
45. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, and Davis MM: Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-96.
46. Skinner PJ, Daniels MA, Schmidt CS, Jameson SC, and Haase AT: Cutting edge: In situ tetramer staining of antigen-specific T cells in tissues. J Immunol 2000;165:613-617.
47. Mansfield KG, Veazey RS, Hancock A, Carville A, Elliott M, Lin KC, and Lackner AA: Induction of disseminated Mycobacterium avium in simian AIDS is dependent upon simian immunodeficiency virus strain and defective granuloma formation. Am J Pathol 2001;159:693-702.
48. Suryanarayana K, Wiltrout TA, Vasquez GM, Hirsch VM, and Lifson JD: Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction. AIDS Res Hum Retroviruses 1998;14:183-189.
49. Lifson JD, Rossio JL, Piatak M, Jr., Parks T, Li L, Kiser R, Coalter V, Fisher B, Flynn BM, Czajak S, Hirsch VM, Reimann KA, Schmitz JE, Ghrayeb J, Bischofberger N, Nowak MA, Desrosiers RC, and Wodarz D: Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol 2001;75:10187-10199.
50. Miller CJ, McGhee JR, and Gardner MB: Mucosal immunity, HIV transmission, and AIDS. Lab Invest 1993;68:129-145.
51. Briskin M, Winsor-Hines D, Shyjan A, Cochran N, Bloom S, Wilson J, McEvoy LM, Butcher EC, Kassam N, Mackay CR, Newman W, and Ringler DJ: Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97-110.
52. Butcher EC, Williams M, Youngman K, Rott L, and Briskin M: Lymphocyte trafficking and regional immunity. Adv Immunol 1999;72:209-253.
53. Kuroda MJ, Schmitz JE, Barouch DH, Craiu A, Allen TM, Sette A, Watkins DI, Forman MA, and Letvin NL: Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med 1998;187:1373-1381.
54. Amara RR, Villinger F, Staprans SI, Altman JD, Montefiori DC, Kozyr NL, Xu Y, Wyatt LS, Earl PL, Herndon JG, McClure HM, Moss B, and Robinson HL: Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol 2002;76:7625-7631.
55. Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, Montefiori D, Roberts A, Buonocore L, and Rose JK: An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001;106:539-549.
56. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, Rosenzweig M, Johnson RP, Desrosiers RC, and Lackner AA: Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998;280:427-431.
57. De Boer RJ, Mohri H, Ho DD, and Perelson AS: Turnover rates of B cells, T cells, and NK cells in simian immunodeficiency virus-infected and uninfected rhesus macaques. J Immunol 2003;170:2479-2487.
58. Muller S and Kohler H: B cell superantigens in HIV-1 infection. Int Rev Immunol 1997;14:339-349.
59. Steger KK, Dykhuizen M, Mitchen JL, Hinds PW, Preuninger BL, Wallace M, Thomson J, Montefiori DC, Lu Y, and Pauza CD: CD4+-T-cell and CD20+-B-cell changes predict rapid disease progression after simian-human immunodeficiency virus infection in macaques. J Virol 1998;72:1600-1605.
60. Malaspina A, Moir S, Kottilil S, Hallahan CW, Ehler LA, Liu S, Planta MA, Chun TW, and Fauci AS: Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function. J Immunol 2003;170:5965-5972.
61. Letvin NL, Barouch DH, and Montefiori DC: Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol 2002;20:73-99.
62. Lockey TD, Slobod KS, Caver TE, D'Costa S, Owens RJ, McClure HM, Compans RW, and Hurwitz JL: Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees. Immunol Res 2000;21:7-21.
63. McElrath MJ, Corey L, Montefiori D, Wolff M, Schwartz D, Keefer M, Belshe R, Graham BS, Matthews T, Wright P, Gorse G, Dolin R, Berman P, Francis D, Duliege AM, Bolognesi D, Stablein D, Ketter N, and Fast P: A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 2000;16:907-919.
64. Montefiori DC and Evans TG: Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. AIDS Res Hum Retroviruses 1999;15:689-698.
65. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR. and Wilson IA: Crystal structure of a neutralizing human IGG against HIV-1: A template for vaccine design. Science 2001;293:1155-1159.
66. Sattentau QJ, Moulard M, Brivet B, Botto F, Guillemot JC, Mondor I, Poignard P, and Ugolini S: Antibody neutralization of HIV-1 and the potential for vaccine design. Immunol Lett 1999;66:143-149.
67. Lamm ME: Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol 1997;51:311-340.
68. Mestecky J and McGhee JR: Immunoglobulin A (IgA): Molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv Immunol 1987;40:153-245.
69. Beyrer C, Artenstein AW, Rugpao S, Stephens H, VanCott TC, Robb ML, Rinkaew M, Birx DL, Khamboonruang C, Zimmerman PA. Nelson KE and Natpratan C: Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group. J Infect Dis 1999;179:59-67.
70. Clerici M, Salvi A, Trabattoni D, Lo Caputo S, Semplici F, Biasin M, Ble C, Meacci F, Romeo C, Piconi S, Mazzotta F, Villa ML, and Mazzoli S: A role for mucosal immunity in resistance to HIV infection. Immunol Lett 1999;66:21-25.
71. Plummer FA, Ball TB, Kimani J, and Fowke KR: Resistance to HIV-1 infection among highly exposed sex workers in Nairobi: What mediates protection and why does it develop? Immunol Lett 1959;66:27-34.
72. Buge SL, Richardson E, Alipanah S, Markham P, Cheng S, Kalyan N, Miller CJ, Lubeck M, Udem S, Eldridge J, and Robert-Guroff M: An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 1997;71:8531-8541.
73. Boyer JD, Chattergoon M, Muthumani K, Kudchodkar S, Kim J, Bagarazzi M, Pavlakis G, Sekaly R, and Weiner DB: Next generation DNA vaccines for HIV-1. J Liposome Res 2002;12:137-142.
74. Dyer JR, Eron JJ, Hoffman IF, Kazembe P, Vernazza PL, Nkata E, Costello Daly C, Fiscus SA, and Cohen MS: Association of CD4 cell depletion and elevated blood and seminal plasma human immunodeficiency virus type 1 (HIV-1) RNA concentrations with genital ulcer disease in HIV-1-infected men in Malawi. J Infect Dis 1998;177:224-227.
75. Dyer JR, Kazembe P, Vernazza PL, Gilliam BL, Maida M, Zimba D, Hoffman IF, Royce RA, Schock JL, Fiscus SA, Cohen MS, and Eron JJ Jr: High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis 1998;177:1742-1746.
76. Bujan L, Daudin M, Alvarez M, Massip P, Puel J, and Pasquier C: Intermittent human immunodeficiency type 1 virus (HIV-1) shedding in semen and efficiency of sperm processing despite high sem-inal HIV-2 RNA levels. Fertil Steril 2002;78:1321-1323.
77. Dunne AL, Mitchell F, Allen KM, Baker HW, Garland S, Clarke GN, Mijch A, and Crowe SM: Analysis of HIV-1 viral load in seminal plasma samples. J Clin Virol 2003;26:239-245.
78. Liuzzi G, Chirianni A, Clementi M, Bagnarelli P, Valenza A, Cataldo PT, and Piazza M: Analysis of HIV-1 load in blood, semen and saliva: Evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS 1996;10:F51-56.
79. Feinberg MB and Moore JP: AIDS vaccine models: Challenging challenge viruses. Nat Med 2002;8:207-210.
80. Goldstein S, Ourmanov I, Brown CR, Beer BE, Elkins WR, Plishka R, Buckler-White A, and Hirsch VM: Wide range of viral load in healthy African green monkeys naturally infected with simian immunodeficiency virus. J Virol 2000;74:11744-11753.
81. Rey-Cuille MA, Berthier JL, Bomsel-Demontoy MC, Chaduc Y, Montagnier L, Hovanessian AG, and Chakrabarti LA: Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. J Virol 1998;72:3872-3886.
82. Villinger F, Brice GT, Mayne A, Bostik P, and Ansari AA: Control mechanisms of virus replication in naturally SIVsmm infected mangabeys and experimentally infected macaques. Immunol Lett 1999;66:37-46.